Institutional members access full text with Ovid®

Share this article on:

Candida Speciation, Antifungal Treatment and Adverse Events in Pediatric Invasive Candidiasis: Results From 441 Infections in a Prospective, Multi-National Study

Palazzi, Debra L. MD*; Arrieta, Antonio MD; Castagnola, Elio MD; Halasa, Natasha MD, MPH§; Hubbard, Sydney MPH; Brozovich, Ava A. MPH; Fisher, Brian T. DO, MSCE; Steinbach, William J. MD

Pediatric Infectious Disease Journal: December 2014 - Volume 33 - Issue 12 - p 1294–1296
doi: 10.1097/INF.0000000000000431
Brief Reports

A multi-national prospective study of pediatric patients with invasive candidiasis between August 2007 and September 2012 was performed and included 441 infections. Variation in infecting Candida species and antifungals used was noted between US and non-US sites. Antifungal-associated adverse events were most common with polyene use.

From the *Baylor College of Medicine and Texas Children’s Hospital, Houston, TX; Children’s Hospital of Orange County, Orange, CA; Istituto Giannina Gaslini, Genova, Italy; §Monroe Carell Jr. Children’s Hospital at Vanderbilt University, Nashville, TN; Children’s Hospital of Philadelphia, Philadelphia, PA; and Duke University, Durham, NC.

Accepted for publication May 21, 2014.

This work was supported in part by an investigator-initiated study protocol funded by Astellas Pharma US. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: William J. Steinbach, MD, Division of Pediatric Infectious Diseases, Department of Pediatrics, Department of Molecular Genetics & Microbiology, 427 Jones Building, Research Drive, Duke University Medical Center, Durham, NC 27710. E-mail: bill.steinbach@duke.edu.

© 2014 by Lippincott Williams & Wilkins, Inc.